- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LEONABIO Aktie jetzt für 0€ handeln | |||||
| 19.08. | Mizuho lowers LeonaBio stock price target on higher OpEx | 1 | Investing.com | ||
| 19.08. | LeonaBio: ELAINE-3 Enrollment Reaches 495 Of About 600 Patients As Up To $146 Million Of Warrant Proceeds Could Support Upcoming Milestones | 1 | pulse2.com | ||
| 17.08. | Citizens lowers LeonaBio stock price target to $17 on valuation | 1 | Investing.com | ||
| 17.08. | Athira Pharma GAAP EPS of -$0.80 misses by $0.27 | 1 | Seeking Alpha | ||
| 14.08. | LeonaBio, Inc.: LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update | 195 | GlobeNewswire (Europe) | On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected... ► Artikel lesen | |
| 30.07. | Citizens upgrades LeonaBio stock rating on breast cancer drug potential | 2 | Investing.com | ||
| 23.06. | LeonaBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | LeonaBio, Inc.: LeonaBio to Participate in Upcoming Medical and Industry Meetings in June | 3 | GlobeNewswire (USA) | ||
| 27.05. | Piper Sandler initiates LeonaBio stock with overweight rating | 2 | Investing.com | ||
| 27.05. | Piper Sandler startet Coverage für LeonaBio mit "Overweight" und hohem Kursziel | 3 | Investing.com Deutsch | ||
| 07.05. | LeonaBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | LeonaBio, Inc.: LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. | 3 | GlobeNewswire (USA) | ||
| 23.04. | LeonaBio, Inc.: LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer | 1 | GlobeNewswire (USA) | ||
| 21.04. | LeonaBio, Inc.: Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio's Data | 1 | GlobeNewswire (USA) | ||
| 07.04. | Cantor Fitzgerald reiterates Overweight on LeonaBio stock | 2 | Investing.com | ||
| 06.04. | Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook | 3 | Investing.com | ||
| 01.04. | LeonaBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.03. | LeonaBio, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 31.03. | LeonaBio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 27.03. | LeonaBio GAAP EPS of -$24.70 | 12 | Seeking Alpha |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,348 | -1,06 % | Rheinmetall-Aktie verkaufen? Evotec mit KI-Fantasie? Lahontan Gold hebt Ressourcenschätzung um 22 %! | Soll man die Rheinmetall-Aktie verkaufen? Dazu rät jedenfalls mwb Research. Die Analysten sehen Rheinmetall operativ weiterhin als klaren Gewinner des europäischen Rüstungsbooms. Doch die Erwartungen... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,950 | +1,99 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| ABIVAX | 97,45 | -0,31 % | Abivax-Aktie: Zulassungsantrag rückt näher - Übernahme auch? | Die Abivax-Aktie steht vor einer entscheidenden Phase: Nach starken Phase-3-Daten, konstruktivem FDA-Feedback und einer prall gefüllten Kasse rückt der geplante Zulassungsantrag für Obefazimod in den... ► Artikel lesen | |
| IBIO | 1,163 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,317 | +1,35 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 6,880 | -1,01 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,260 | +1,29 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| LAKEFRONT BIOTHERAPEUTICS | 25,080 | +0,16 % | Lakefront Biotherapeutics: Lakefront Receives Transparency Notification from Bank of America | Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
Pursuant... ► Artikel lesen | |
| MYRIAD GENETICS | 2,727 | +0,44 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,520 | -0,40 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| MANNKIND | 3,395 | 0,00 % | MannKind-Aktie: Biotech-Chance mit neuen Wachstumstreibern | Die MannKind-Aktie steht nach zwei wichtigen FDA-Zulassungen vor einer neuen Wachstumsphase. Bei einer Marktkapitalisierung von rund 1,24 Milliarden US-Dollar könnte der Markt das langfristige Potenzial... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,840 | +4,02 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,064 | +0,66 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen |
Das Unternehmen LEONABIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 8,000 Euro und damit +2,17 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEONABIO INC finden Sie auf Wallstreet Online.